You are here

P&T® Journal contents for April 2007

Features

Editor’s Memo
P&T pays tribute to a long-time columnist and medical writer, Lawrence Prescott, PhD.
Sonja Sherritze
Commentary
As with many well-intentioned feel-good initiatives, achieving the goals of the Medication Reconciliation Project will be a lot more difficult than dreaming them up.
Nancy Greengold, MD, MBA
Opinion
Stimulant drugs, considered a first-line therapy for ADHD, have a potential for misuse and abuse. A new agent may have less potential for these problems.
Frank A. López, MD
Cover Story
As a therapy for bleeding, rFVIIa is often prescribed for off-label indications, and this trend is increasing. The authors suggest possible new prescribing guidelines.
Sandra Magnetti, MS, DrPH, Michael Oinonen, PharmD, MPH, and Karl A. Matuszewski, MS, PharmD
Meeting Highlights
The author reviews therapies for multiple myeloma, chronic myeloid leukemia, paroxysmal nocturnal hemolysis, and B-cell chronic lymphocytic leukemia.
Walter Alexander
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial
David Nash, MD, MBA, summarizes a series of reports on global trends for a sustainable health care system of the future in terms of health care spending, shared financial risks among private and public payers, and the continuing need for transparency in the quality and pricing of health care.
Marvin M. Goldenberg, PhD, RPh, MS
Medication Errors
Matthew Grissinger, RPh, FASCP, discusses problems with color coding in pharmaceutical products.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas predicts that it will be a lot easier for Congress to authorize the FDA to oversee the approval of generic biotech drugs than it will be for the FDA to implement the approval process.
Stephen Barlas
P&T presents the latest information from the FDA.
Drug Forecast
The authors review rimonabant (Acomplia) for the treatment of obesity.
Carla A. Luque, PharmD, Megan J. Ehret, PharmD, and Jose A. Rey, PharmD, BCPP